|
|
Ming Gong, Melinda Wilson, Thomas Kelly, Wen Su, James Dressman, Jeanie Kincer, Sergey V. Matveev, Ling Guo, Theresa Guerin, Xiang-An Li, Weifei Zhu, Annette Uittenbogaard, Eric J. Smart
J Clin Invest. 2003;
111(10):1579
doi:10.1172/JCI16777
Abstract |
Full text
| PDF

C
ardiovascular diseases remain the leading cause of death in the United States. Two factors associated with a decreased risk of developing cardiovascular disease are elevated HDL levels and sex — specifically, a decreased risk is found in premenopausal women. HDL and estrogen stimulate eNOS and the production of nitric oxide, which has numerous protective effects in the vascular system including vasodilation, antiadhesion, and anti-inflammatory effects. We tested the hypothesis that HDL binds to its receptor, scavenger receptor class B type I (SR-BI), and delivers estrogen to eNOS, thereby stimulating the enzyme. HDL isolated from women stimulated eNOS, whereas HDL isolated from men had minimal activity. Studies with ovariectomized and ovariectomized/estrogen replacement mouse models demonstrated that HDL-associated estradiol stimulation of eNOS is SR-BI dependent. Furthermore, female HDL, but not male HDL, promoted the relaxation of muscle strips isolated from C57BL/6 mice but not SR-BI null mice. Finally, HDL isolated from premenopausal women or postmenopausal women receiving estradiol replacement therapy stimulated eNOS, whereas HDL isolated from postmenopausal women did not stimulate eNOS. We conclude that HDL-associated estrodial is capable of the stimulating eNOS. These studies establish a new paradigm for examining the cardiovascular effects of HDL and estrogen.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(14)
| Title and authors |
Publication |
Year |
Redox Control of Endothelial Function and Dysfunction: Molecular Mechanisms and Therapeutic Opportunities
Shane R. Thomas, Paul K. Witting, Grant R. Drummond
|
Antioxidants & Redox Signaling
|
2008 |
Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins
A. R. Tall
|
Journal of Internal Medicine
|
2008 |
Steroid Hormone–Fatty Acid Esters and Bone
Maija H Badeau, Robert Badeau, Matti Jauhiainen, Matti J Tikkanen
|
Journal of Bone and Mineral Research
|
2008 |
Impact of Vitamin A on High-Density Lipoprotein-Cholesterol and Scavenger Receptor Class BI in the Obese Rat
Shanmugam M. Jeyakumar, Ayyalasomayajula Vajreswari, Nappan V. Giridharan
|
Obesity
|
2007 |
Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL
Vassilis I. Zannis, Angeliki Chroni, Monty Krieger
|
J Mol Med
|
2006 |
Lipids and the endothelium: an update
Andrew J Murphy, Dmitri Sviridov, Jaye PF Chin-Dusting
|
Future Lipidology
|
2006 |
THE REGULATION AND PHARMACOLOGY OF ENDOTHELIAL NITRIC OXIDE SYNTHASE
David M. Dudzinski, Junsuke Igarashi, Daniel Greif, Thomas Michel
|
Annu. Rev. Pharmacol. Toxicol.
|
2006 |
Signal transduction underlying the vascular effects of sphingosine 1-phosphate and sphingosylphosphorylcholine
Denise G. Hemmings
|
Naunyn-Schmied Arch Pharmacol
|
2006 |
A central role of eNOS in the protective effect of wine against metabolic syndrome
Federico Leighton, Soledad Miranda-Rottmann, Inés Urquiaga
|
Cell Biochem. Funct.
|
2006 |
HDL as a target in the treatment of atherosclerotic cardiovascular disease
Patrick Linsel-Nitschke, Alan R. Tall
|
Nat Rev Drug Discov
|
2005 |
|